SCHEMBL2895573

SCHEMBL2895573

O=C1c2c(O)c(=O)n(CC3CCCCC3)c(=S)n2CCN1Cc1ccc(F)cc1

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GRM2 Q14416 3/20 0.38
KCNH2 Q12809 2/20 0.38
TP53 P04637 1/20 0.38
CNR1 P21554 2/20 0.38
CNR2 P34972 2/20 0.38
KDM4E B2RXH2 1/20 0.38
ALDH1A1 P00352 1/20 0.38
GRIN2B Q13224 1/20 0.37
AKR1B1 P15121 1/20 0.37
MEN1 O00255 1/20 0.36
LMNA P02545 1/20 0.36
KMT2A Q03164 1/20 0.36
RAB9A P51151 2/20 0.36
POLB P06746 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
CYP2D6 P10635 1/20 0.36
HRH3 Q9Y5N1 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4682779 0.77 GRM2 (0.44) GRM2KCNH2TP53AKR1B1MEN1
SCHEMBL2898693 0.77 NPSR1 (0.47) GRM2KCNH2TP53CNR1CNR2
SCHEMBL2900488 0.77 NPSR1 (0.47) GRM2KCNH2TP53CNR1CNR2
SCHEMBL2898715 0.76 NPSR1 (0.48) GRM2KCNH2TP53ALDH1A1GRIN2B
SCHEMBL2898869 0.75 KCNH2 (0.37) GRM2KCNH2TP53GRIN2BAKR1B1
SCHEMBL2898063 0.75 ALDH1A1 (0.42) GRM2KCNH2KDM4EALDH1A1MEN1
SCHEMBL2898773 0.74 TSHR (0.46) GRM2KCNH2TP53ALDH1A1GRIN2B
SCHEMBL3914367 0.74 KCNH2 (0.35) GRM2KCNH2TP53CNR1CNR2
SCHEMBL3906453 0.74 CCR3 (0.39) MEN1LMNAKMT2ACYP2D6
SCHEMBL2899197 0.73 KCNH2 (0.39) GRM2KCNH2TP53ALDH1A1GRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080009490-A1 Hiv Integrase Inhibitors MERCK SHARP & DOHME CORP. 2008-01-10 US claimed
US-7820680-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2010-10-26 US disclosed
US-7820680-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2010-10-26 US disclosed
US-7820680-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2010-10-26 US disclosed
US-20080009490-A1 Hiv Integrase Inhibitors MERCK SHARP & DOHME CORP. 2008-01-10 US disclosed
US-20080009490-A1 Hiv Integrase Inhibitors MERCK SHARP & DOHME CORP. 2008-01-10 US disclosed
US-20080009490-A1 Hiv Integrase Inhibitors MERCK SHARP & DOHME CORP. 2008-01-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080009490-A1 Hiv Integrase Inhibitors TYMS, UNG, TYMP GRM2 4668/4885KCNH2 3441/4885TP53 564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.